Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT07726069
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cannabinoid Hyperemesis Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Haloperidol — DRUG
    This intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason.

Study Details

Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.

Key Dates

First listed
Jul 24, 2026
Start date
Nov 30, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients who will receive haloperidol
    Patients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis

Primary Outcome Measure

Rate of return to the emergency department [ Time Frame: 1 month ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois HospitalChicagoIllinois60612
Mason A Bartman, MD
[email protected]
8178972205
Wesley Eilbert, MD
[email protected]
6302944225
Mason A Bartman, MD (PRINCIPAL_INVESTIGATOR)
Wesley Eilbert, MD (PRINCIPAL_INVESTIGATOR)
Shaveta Khosla, Khosla (SUB_INVESTIGATOR)
Drew Posen, PharmD (SUB_INVESTIGATOR)
Urvi Dubey, BS (SUB_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
University of Illinois Hospital· Chicago, IL

Related Studies